ArticleMicrobiome2017
The effects of inhaled aztreonam on the cystic fibrosis lung microbiome.
Article in Microbiome, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 59 citations in OpenAlex.
- Article
- Article
- Sex Differences in Lung Immunity.Immunological reviews · 2026Review
- Towards airway microbiome engineering for improving respiratory health.Advanced drug delivery reviews · 2025Review
- Positioning the preventive potential of microbiome treatments for cystic fibrosis in the context of current therapies.Cell reports. Medicine · 2024Review
- The airway microbiome of persons with cystic fibrosis correlates with acquisition and microbiological outcomes of incidentFrontiers in microbiology · 2024Article
- Drug-microbiota interactions: an emerging priority for precision medicine.Signal transduction and targeted therapy · 2023Review
- Genome-wide mapping of gene-microbe interactions in the murine lung microbiota based on quantitative microbial profiling.Animal microbiome · 2023Article
- Community composition shapes microbial-specific phenotypes in a cystic fibrosis polymicrobial model system.eLife · 2023Article
- Exploring the Cystic Fibrosis Lung Microbiome: Making the Most of a Sticky Situation.Journal of the Pediatric Infectious Diseases Society · 2022Review
- Therapeutic Targeting of the Respiratory Microbiome.American journal of respiratory and critical care medicine · 2022Article
- Multidrug-Resistant Bacteria in Children and Adolescents with Cystic Fibrosis.Children (Basel, Switzerland) · 2022Article
- Lipid-Based Drug Delivery Systems for Diseases Managements.Biomedicines · 2022Review
- Differences of the Nasal Microbiome and Mycobiome by Clinical Characteristics of COPD Patients.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2022Article
- Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2021Article
- Polymicrobial Interactions in the Cystic Fibrosis Airway Microbiome Impact the Antimicrobial Susceptibility ofAntibiotics (Basel, Switzerland) · 2021Review
- Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.Clinical pharmacokinetics · 2021Review
- Azithromycin and the microbiota of cystic fibrosis sputum.BMC microbiology · 2021Article
- Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives.Antibiotics (Basel, Switzerland) · 2021Review
- The Human Microbiome, an Emerging Key-Player in the Sex Gap in Respiratory Diseases.Frontiers in medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAztreonam lysine for inhalation (AZLI) is an inhaled antibiotic used to treat chronic Pseudomonas aeruginosa infection in CF. AZLI improves lung function and quality of life, and reduces exacerbations-improvements attributed to its antipseudomonal activity. Given the extremely high aztreonam concentrations achieved in the lower airways by nebulization, we speculate this may extend its spectrum of activity to other organisms. As such, we sought to determine if AZLI affects the CF lung microbiome and whether community constituents can be used to predict treatment responsiveness.
methodsPatients were included if they had chronic P. aeruginosa infection and repeated sputum samples collected before and after AZLI. Sputum DNA was extracted, and the V3-hypervariable region of the 16S ribosomal RNA (rRNA) gene amplified and sequenced.
resultsTwenty-four patients naïve to AZLI contributed 162 samples. The cohort had a median age of 37.1 years, and a median FEV
conclusionsResults from our study suggest potential alternate/additional mechanisms by which AZLI functions. Moreover, our study suggests that the CF microbiota may be used as a biomarker to predict patient responsiveness to therapy suggesting the microbiome may be harnessed for the personalization of therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.